IDYA IDEAYA Biosciences, Inc.
Price Chart
Executive Summary
IDEAYA announced a clinical collaboration with Roche to evaluate its PRMT5 inhibitor IDE892 in combination with Roche's pan-RAS inhibitor RG6505 for MTAP-deleted, RAS-mutant pancreatic cancer (PDAC). IDEAYA will sponsor the trial and Roche will supply RG6505; each party retains full commercial rights to its own compounds. This is an early-stage, non-financial collaboration that validates IDEAYA's MTAP-deletion portfolio but carries no near-term revenue or milestone payments.
Actionable Insight
This collaboration provides clinical validation for IDEAYA's PRMT5 program and access to Roche's pan-RAS inhibitor, but with no near-term financial catalysts. Monitor for Phase 1 data readouts and potential expansion into triplet combinations. The stock may see modest positive sentiment from the partnership, but fundamental value remains tied to clinical execution.
Key Facts
- IDEAYA entered a clinical collaboration with Roche to evaluate IDE892 (PRMT5 inhibitor) + RG6505 (pan-RAS inhibitor) in MTAP-deleted RAS-mutant PDAC.
- IDEAYA sponsors the trial; Roche supplies RG6505.
- Each party retains all commercial rights to its own compounds; no financial terms disclosed.
- MTAP deletion estimated in up to 40% of PDAC; almost all MTAP-deleted PDAC harbor RAS mutations.
- IDE892 is in Phase 1 dose escalation; combination cohorts planned in PDAC, NSCLC, and other solid tumors.
- Triplet combination with IDE397 (MAT2A inhibitor) possible upon joint approval.
Financial Impact
No financial terms disclosed; no upfront, milestone, or royalty payments mentioned.
Risk Factors
- Early-stage clinical risk — preclinical results may not translate to human efficacy.
- No financial terms disclosed; collaboration provides no near-term revenue or milestone payments.
- Dependence on Roche for drug supply and joint governance may slow trial execution.
- Competitive landscape for PRMT5 and RAS-targeted therapies is evolving.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-254476 |
| Document: 0001193125-26-254476-index-headers.html | 0001193125-26-254476 |
| Document: 0001193125-26-254476-index.html | 0001193125-26-254476 |
| Document: 0001193125-26-254476.txt | 0001193125-26-254476 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
2d ago
|
8-K
| — | awaiting T+20 | — | — |
|
May 5, 2026
4w ago
|
8-K
| $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $28.29 (−1.57%) |
|
May 5, 2026
4w ago
|
424B5
| $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $28.29 (−1.57%) |
|
Apr 13, 2026
7w ago
|
8-K
| $32.82 $28.13 | ▼ −14.29% | ▼ −22.02% | $28.29 (−13.80%) |
|
Apr 9, 2026
8w ago
|
8-K
| $31.00 $28.74 | ▼ −7.29% | ▼ −14.86% | $28.29 (−8.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access